Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Current Deferred Revenue (2023 - 2025)

BioScience Health Innovations (BHIC) has disclosed Current Deferred Revenue for 3 consecutive years, with $136590.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 461.43% to $136590.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $136590.0 through Dec 2025, up 461.43% year-over-year, with the annual reading at $136590.0 for FY2025, 461.43% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $136590.0 at BioScience Health Innovations, up from $110991.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $248659.0 in Q2 2025, with the low at $3949.0 in Q4 2023.
  • Average Current Deferred Revenue over 3 years is $95759.3, with a median of $80514.5 recorded in 2025.
  • The sharpest move saw Current Deferred Revenue surged 516.08% in 2024, then soared 461.43% in 2025.
  • Over 3 years, Current Deferred Revenue stood at $3949.0 in 2023, then soared by 516.08% to $24329.0 in 2024, then skyrocketed by 461.43% to $136590.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $136590.0, $110991.0, and $248659.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.